EDUCATION

Medical School

  • University of Vermont College of Medicine , 2004 , Burlington , VT

Residency

Pediatrics
  • Rhode Island Hospital , 2007 , Providence , RI

Fellowship

Pediatric Infectious Diseases
  • Boston Children's Hospital , 2010 , Boston , MA

Philosophy of Care

The opportunity to contribute to the care and healing of people during a time that is often one of the most challenging of their lives inspired me to become a physician. When faced with a difficult to diagnose illness or an infection that is challenging to treat, every component of a patient’s underlying health and goals of care should be considered, and every patient is unique. As a pediatric infectious diseases provider, I strive to work collaboratively with each patient, family and care team to offer the most comprehensive and patient-centered guidance possible to diagnose, optimally treat, and prevent infections.

PROFESSIONAL HISTORY

Dr. Moffitt joined the faculty of the Pediatric Infectious Diseases Division at Boston Children’s Hospital upon completion of her fellowship training in 2010. In her last year of fellowship, she received the Kass Award for Excellence in Clinical Care from the Massachusetts Infectious Diseases Society and has since received awards from the Pediatric Infectious Diseases Society and the Charles Hood Foundation to support her research in bacterial vaccine development and immunity to bacterial infections. In addition to caring for patients seen by the Infectious Diseases consult service, Dr. Moffitt devotes her time to studying how bacteria cause disease. Of particular interest is furthering our understanding of how people develop immunity to infection with several common bacteria, such as Staphylococcus aureus. Through several clinical and translational studies, Dr. Moffitt is investigating the role of specific bacterial factors during infection and immune responses in affected patients and hopes that findings from this research will contribute to the development of therapies to prevent and treat such infections.

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Infectious Diseases

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Randolph AG, Xu R, Novak T, Newhams MM, Bubeck Wardenburg J, Weiss SL, Sanders RC, Thomas NJ, Hall MW, Tarquinio KM, Cvijanovich N, Gedeit RG, Truemper EJ, Markovitz B, Hartman ME, Ackerman KG, Giuliano JS, Shein SL, Moffitt K. Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children with Influenza-Related Critical Illness. Clin Infect Dis. 2018 Jun 09. View abstract
  2. Moffitt K, Cheung E, Manis J, Malley R. Evaluation of the Role of stat3 in Antibody and TH17-Mediated Responses to Pneumococcal Immunization and Infection by Use of a Mouse Model of Autosomal Dominant Hyper-IgE Syndrome. Infect Immun. 2018 05; 86(5). View abstract
  3. Campos IB, Herd M, Moffitt KL, Lu YJ, Darrieux M, Malley R, Leite LC, Gonçalves VM. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine. 2017 03 01; 35(9):1306-1315. View abstract
  4. Koegel AK, Hofmann I, Moffitt K, Degar B, Duncan C, Tubman VN. Acute lymphoblastic leukemia in a patient with MonoMAC syndrome/GATA2 haploinsufficiency. Pediatr Blood Cancer. 2016 10; 63(10):1844-7. View abstract
  5. Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother. 2016; 12(2):383-92. View abstract
  6. Moffitt K, Howard A, Martin S, Cheung E, Herd M, Basset A, Malley R. T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins. Clin Vaccine Immunol. 2015 Aug; 22(8):909-16. View abstract
  7. Moffitt K, Skoberne M, Howard A, Gavrilescu LC, Gierahn T, Munzer S, Dixit B, Giannasca P, Flechtner JB, Malley R. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun. 2014 May; 82(5):2079-86. View abstract
  8. Schwenk HT, Vo P, Moffitt K, Kehoe E, Blume E, Sharma T, Khatwa U. Allograft-Transmitted Histoplasma capsulatum Infection in a Solid Organ Transplant Recipient. J Pediatric Infect Dis Soc. 2013 Sep; 2(3):270-3. View abstract
  9. Moffitt KL, Malley R, Lu YJ. Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine. PLoS One. 2012; 7(8):e43445. View abstract
  10. Moffitt KL, Yadav P, Weinberger DM, Anderson PW, Malley R. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine. 2012 Jun 19; 30(29):4316-22. View abstract
  11. Recher M, Burns SO, de la Fuente MA, Volpi S, Dahlberg C, Walter JE, Moffitt K, Mathew D, Honke N, Lang PA, Patrizi L, Falet H, Keszei M, Mizui M, Csizmadia E, Candotti F, Nadeau K, Bouma G, Delmonte OM, Frugoni F, Fomin AB, Buchbinder D, Lundequist EM, Massaad MJ, Tsokos GC, Hartwig J, Manis J, Terhorst C, Geha RS, Snapper S, Lang KS, Malley R, Westerberg L, Thrasher AJ, Notarangelo LD. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood. 2012 Mar 22; 119(12):2819-28. View abstract
  12. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol. 2011 Jun; 23(3):407-13. View abstract
  13. Moffitt KL, Gierahn TM, Lu Y, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley R . Cell Host and Microbe. TH17-based vaccine design for prevention of Streptococcus pneumoniae colonization. 2011; 9(2):158-65. View abstract